ABSTRACT BACKGROUND
METHODS

HOSPITAL QUALITY AND PATIENT CHOICE
This study uses data from the New York State Inpatient Database, which includes 10 million discharges from all hospitals in New York State between 2009 and 2012. We identified discharges related to isolated mitral valve procedures through its clinical codes 35.12, 35.13 and 35.24 based on International Classification of Disease (9 th revision) and focused on only elective cases. Patients were excluded if they were less than 30 years old, had coronary revascularization, congenital heart disease, excision of ventricular aneurysm, replacement of thoracic aorta, aortic fenestration procedure, closed heart valvuloplasty, heart transplant, or other valvular repair or replacement. 6 Patients were also excluded if they travelled from other states to New York or if they were Native American (less than 1% of the sample). This resulted in 2,718 patients treated in 35 hospitals over the four year interval.
To measure the gap in repair rates between CoEs and non-CoEs, we used a probit model with procedure type (i.e., repair or replacement) as the dependent variable. Included in the probit model were independent variables of patients' demographics, insurance type and comorbidities.
Since patients are not randomly assigned to hospitals, we cannot directly compare observed repair rates between hospitals. To correct for a potential selection bias if patients who are more likely to benefit from a CoE were also more likely to choose a CoE, we constructed a distancebased instrumental variable, which correlates with the probability of choosing a CoE but not with patient characteristics. 7 To understand which factors affect patients' choices of hospitals, we used a probit model with the choice of a CoE vs a non-CoE as the dependent variable. The independent variables are patient demographics, insurance type, extra travel distance to the nearest CoE and a dummy indicating whether the patient has a local CoE (i.e., within 5 miles to the nearest hospital).
COST-BENEFIT MODEL
To evaluate the impact of hospital choice, we constructed a model to characterize short-and long-term costs to both patients and payers. Based on the steps and contingencies associated with mitral valve diseases (see Figure S2 in the Supplementary Appendix for a schematic), our model includes: (1) travel cost, (2) procedure cost, (3) cost of reoperation, (4) cost of stroke, (5) cost of bleeding, (6) cost of maintenance (i.e., warfarin for anticoagulation) for mechanical valve replacement, and (7) cost of Structural Valve Deterioration (SVD) for biological valve replacement. We estimated these costs for patients without comorbidities (which we refer to as "standard" patients) and for patients with common comorbidities, including heart failure, chronic lung disease, diabetes, hypertension, renal disease, and atrial fibrillation. 4 We calculated costs to patients associated with treatment in a given hospital as: where costs over time were converted to net present value of payments using a 5% discount rate.
iii Finally, for both patients and payers, we computed the net benefit from a CoE as the difference between the expected cost at a non-CoE hospital and that at a CoE. 
MODEL ELEMENTS
RESULTS
HOSPITAL QUALITY
The likelihood of receiving a repair is influenced by both hospital and patient characteristics. By definition CoEs had significantly higher repair rates ( 
PATIENT CHOICE
Among the 2,718 patients in our analysis, 1,097 (40.4%) chose a CoE (see Table 3 ). This percentage strongly correlates with patients' distance to the nearest CoE, suggesting distance is an important factor affecting how patients chose hospitals. 
LIFE EXPECTANCY
Our model estimates that the life expectancy a patient gained from going to a CoE instead of a non-CoE ranged from 3.77-9.88 months depending on the patient's age and comorbidities (Table   4 , top). Generally speaking, patients in their 70s benefited the most. However, existence of comorbidities reduced the benefits from a CoE for all age groups. The relationship between patients' age and benefits is not linear, because younger patients were more likely to receive a mechanical valve replacement, which is both more durable and more hazardous (with respect to stroke risk) than a biological valve.
We converted life expectancy into monetary value using the formula 1000k × age -0.66 . 18 For patients with mitral valve replacement, this number was further discounted by yearly mortality rates associated with biological or mechanical valve replacement. The results are summarized in Table 4 (middle). This shows that patients' benefit ranged from $7,548 (for patients in their 80s
with heart failure) to $28,508 (for patients in their 70s with no comorbidities). 18 ‡ Cost to payers refers to the difference between cost at CoEs and that at non-CoEs. We estimate that mitral valve repair costs $46,000 and mitral valve replacement costs $53,000 at non-CoE hospitals and both costs are $4,000 higher at CoEs.
COSTS TO THE PAYERS
Costs to payers also depend on a patient's age and comorbidities (Table 6 , bottom). Estimating these costs by using the sources in Table 1 and our statistical estimates of the increased likelihood of receiving a repair from a CoE indicates that payers obtained positive savings through treatment at a CoE for patients of all age groups and all comorbidities. Per patient benefit to payers ranged from $1,231 (for patients in their 80s with diabetes) to $8,075 (for patients in their 60s with no comorbidities).
SOCIETAL BENEFIT
We calculated societal benefits by adding the net savings to patients and payers (See Table S1 in the Supplementary Appendix). Societal benefits were positive for all age groups and all comorbidities, ranging from $9,834 (for patients in their 80s with renal disease) to $32,959 (for patients in their 70s with no comorbidities).
DISCUSSION
Mitral valve repair is superior to mitral valve replacement for all age groups and all comorbidities for isolated degenerative mitral valve disease. Based on inpatient discharge data from New York State 2009-2012, our study suggests that CoEs have significantly higher repair rates than non-CoEs with an average gap in risk adjusted repair rate of around around 24%.
Despite this, roughly 60% of patients in the New York cohort failed to choose a CoE, and therefore some of them missed the opportunity to receive medically beneficial mitral valve repairs. This study shows that distance and insurance type are two important factors affecting patients' choice of a CoE.
Our model predicts that referral of mitral patients to a CoE as outlined in the 2014 American Heart Association/American College of Cardiology Valvular Heart Disease Guidelines would benefit patients of all age groups and all comorbidities. However, the net savings vary widely for different age groups and different comorbidities, ranging from $7,548 to $28,508.
Directing patients to CoEs benefits payers as well, because long-term reductions in costs of complications are sufficient to offset the higher short-term procedure cost at a CoE. Therefore, the economic incentives of patients and payers align (Table 4) . Presumably, better dissemination of information about the clinical and economic benefits of mitral valve surgery at a CoE would result in more of these patients going to a CoE.
We should note, however, that referring all patients to CoEs, as recommended by the Valvular Heart Disease Guidelines, could create longer travel distance and capacity problems for treatment at the CoEs. Our model predicts that, if patients were referred to the nearest CoE, overall repair rate would increase by 26%, patients would need to travel 11 miles further on average, and CoEs would experience 150% increase in volume. Furthermore, encouraging all patients to go to CoEs could retard the establishment and maintenance of proficiency of other hospitals.
Finally, the gap of repair rate between CoEs and non-CoEs is not uniform across patients of differing levels of case complexity, which suggests that the incentives of patients and payers are not necessarily aligned for each individual patient. Better prediction is needed to identify which patients are most likely to benefit from the sophistication and experience of a CoE. For instance, it may be possible for a cardiologist or surgeon to analyze the preoperative echocardiogram to estimate the repairability of a patient's mitral valve. For purposes of illustration, suppose that these estimates are classified into low, moderate and high and that outcome data for hospitals are stratified according to these classifications. Then, as illustrated in Figure 1 , the repair rate gap between CoEs and non-CoEs is likely to be small for the low category (some patients will get their mitral valve repaired at a CoE or a non-CoE) and for the high category (some patients with unrepairable mitral valve will get a replacement even if they visit a CoE). Hence, neither patients in these categories nor their payers will have strong incentives to choose a CoE. But for the moderate repairability category, the gap between CoEs and non-CoEs will be sufficiently large to result in substantial benefits to both patients and payers. By routing only those patients who benefit most to CoEs, the limited capacity of CoEs will be applied in a manner that produces the greatest societal value.
' Figure 1. Mitral Valve Reparability & Quality Gap between CoEs and Non-CoEs
In conclusion, our results suggest that both patients and payers can benefit from referring mitral patients to CoEs. Under current conditions, such referral generally implies an increased shortterm cost premium at CoEs. But these costs are overweighed by long-term savings to payers and substantial gains to patients. Making properly risk and selection bias adjusted outcome data widely available will lead to better provider selection, which in turn will result in improved longterm outcomes and a reduction in medical costs for patients with mitral valve disease. The dependent variable is whether a patient received mitral valve repair. Independent variables are patient demographics, comorbidities, hospitals' mitral volume, and hospital dummies. Distance is used as an instrument for mitral volume to correct for the potential selection bias that patients who choose high-volume hospitals are also those who are more likely to benefit from high-volume hospitals. * Hospitals with indexes 30-35 have repair rates that are significantly higher than the average. These six hospitals are called CoEs in this study. 
Supplementary Appendix
MODEL ELEMENTS
There is no single source or paper that provides all the data required in our model. Therefore, we drew from several sources in the medical literature to estimate the various parameters. When necessary, we supplemented the literature review by estimates from existing datasets including Society of Thoracic Surgeons (STS) National Database and National Inpatient Sample Data. All costs and benefits have been converted into 2014 US dollars.
Below we discuss our estimates and sources of each model element for patients of different ages, with and without comorbidities. We consider common comorbidities including heart failure, chronic lung disease, diabetes, hypertension, and renal disease 
